Lindbrook Capital, LLC Cytek Biosciences, Inc. Transaction History
Lindbrook Capital, LLC
- $1.09 Billion
- Q4 2024
A detailed history of Lindbrook Capital, LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 94 shares of CTKB stock, worth $376. This represents 0.0% of its overall portfolio holdings.
Number of Shares
94Holding current value
$376% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CTKB
# of Institutions
150Shares Held
72.5MCall Options Held
1KPut Options Held
0-
Black Rock Inc. New York, NY17.1MShares$68.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$46.9 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD8.25MShares$33 Million1.27% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$26.6 Million1.65% of portfolio
-
State Street Corp Boston, MA4.51MShares$18 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $539M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...